Tissue Tek O.C.T. Compound
To Order Contact us: lieven@wlsolutions.be
Compound 401 |
||
| HY-19341 | 10mM/1mL | EUR 186 |
Compound CL0485 |
||
| ADC-P-074 | unit | Ask for price |
Imidazoquinoline Compound |
||
| VAdv-Ly0028 | 5 mg | EUR 3280 |
|
Description: Imidazoquinoline compound, a TLR7 agonist vaccine adjuvant. |
||
Compound 34 |
||
| GL2080-1MG | 1 mg | EUR 373 |
Compound 34 |
||
| GL2080-200UG | 200 ug | EUR 166 |
Compound 112254 |
||
| GL3740-10MG | 10 mg | EUR 166 |
Compound 112254 |
||
| GL3740-50MG | 50 mg | EUR 459 |
Compound E |
||
| GL3746-1MG | 1 mg | EUR 378 |
Compound E |
||
| GL3746-250UG | 250 ug | EUR 172 |
Compound E |
||
| GL3746-5MG | 5 mg | EUR 998 |
Compound W |
||
| A4401-50 | 50 mg | EUR 177 |
|
Description: Inhibitor of ?-secretase; causes a decrease in the released levels of A?42 and notch-1 A?-like peptide 25 (N?25). |
||
Compound 401 |
||
| B7337-10 | 10 mg | EUR 224 |
Compound 401 |
||
| B7337-25 | 25 mg | EUR 441 |
Compound 401 |
||
| B7337-5 | 5 mg | EUR 180 |
Compound K |
||
| N1890-20 | 20 mg | EUR 340 |
|
Description: Compound K |
||
Compound 56 |
||
| A8197-.5 | 500 µg | EUR 108 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-5 | 5 mg | EUR 224 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-5.1 | 10 mM (in 1mL DMSO) | EUR 270 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-S | Evaluation Sample | EUR 81 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 401 |
||
| 1657-5 | EUR 238 | |
Compound 1 |
||
| 1688-5 | EUR 207 | |
Compound 34 |
||
| 1898-1000 | EUR 457 | |
Compound 34 |
||
| 1898-200 | EUR 158 | |
Compound E |
||
| 1949-1000 | EUR 370 | |
Compound E |
||
| 1949-250 | EUR 153 | |
Compound W |
||
| 2208-250 | EUR 300 | |
Compound W |
||
| 2208-50 | EUR 115 | |
Compound 112254 |
||
| 2573-25 | EUR 588 | |
Compound 112254 |
||
| 2573-5 | EUR 185 | |
TEK siRNA |
||
| 20-abx936459 |
|
|
TEK Antibody |
||
| 37274-100ul | 100ul | EUR 252 |
TEK Antibody |
||
| 1-CSB-PA041300 |
|
|
|
Description: A polyclonal antibody against TEK. Recognizes TEK from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100 |
||
TEK Antibody |
||
| 1-CSB-PA050236 |
|
|
|
Description: A polyclonal antibody against TEK. Recognizes TEK from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/5000 |
||
TEK Antibody |
||
| 1-CSB-PA050237 |
|
|
|
Description: A polyclonal antibody against TEK. Recognizes TEK from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000 |
||
TEK Antibody |
||
| 1-CSB-PA023375GA01HU |
|
|
|
Description: A polyclonal antibody against TEK. Recognizes TEK from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
||
TEK Antibody |
||
| 1-CSB-PA982820 |
|
|
|
Description: A polyclonal antibody against TEK. Recognizes TEK from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:3000-1:10000, IHC:1:50-1:200 |
||
anti-TEK |
||
| YF-PA27377 | 50 ug | EUR 363 |
|
Description: Mouse polyclonal to TEK |
||
TEK antibody |
||
| 70R-20759 | 50 ul | EUR 435 |
|
Description: Rabbit polyclonal TEK antibody |
||
Antiasthmatic Compound 1 |
||
| HY-U00409 | 1mg | EUR 849 |
Antibacterial compound 2 |
||
| HY-101730 | 5mg | EUR 7984 |
Antibacterial compound 1 |
||
| HY-101819 | 5mg | EUR 2198 |
Teijin compound 1 |
||
| HY-108323 | 5mg | EUR 312 |
APHA Compound 8 |
||
| M45003 | 1 mg | EUR 284.9 |
|
Description: Ask the seller for details |
||
Compound 112254 hydrochloride |
||
| GL8859-10MG | 10 mg | EUR 166 |
Compound 112254 hydrochloride |
||
| GL8859-50MG | 50 mg | EUR 459 |
Dorsomorphin (Compound C) |
||
| B3252-10 | 10 mg | EUR 137 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Dorsomorphin (Compound C) |
||
| B3252-5 | 5 mg | EUR 108 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Dorsomorphin (Compound C) |
||
| B3252-50 | 50 mg | EUR 340 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Teijin compound 1 |
||
| B5468-10 | 10 mg | EUR 389 |
Teijin compound 1 |
||
| B5468-50 | 50 mg | EUR 1476 |
GPR120 Compound A |
||
| C5824-10 | 10 mg | EUR 293 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
GPR120 Compound A |
||
| C5824-5 | 5 mg | EUR 197 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
GPR120 Compound A |
||
| C5824-50 | 50 mg | EUR 920 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
TEK Rabbit pAb |
||
| A0743-100ul | 100 ul | EUR 308 |
TEK Rabbit pAb |
||
| A0743-200ul | 200 ul | EUR 459 |
TEK Rabbit pAb |
||
| A0743-20ul | 20 ul | EUR 183 |
TEK Rabbit pAb |
||
| A0743-50ul | 50 ul | EUR 223 |
Anti-TEK antibody |
||
| STJ25807 | 100 µl | EUR 277 |
|
Description: This gene encodes a receptor that belongs to the protein tyrosine kinase Tie2 family. The encoded protein possesses a unique extracellular region that contains two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin type III repeats. The ligand angiopoietin-1 binds to this receptor and mediates a signaling pathway that functions in embryonic vascular development. Mutations in this gene are associated with inherited venous malformations of the skin and mucous membranes. Alternative splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. |
||
Anti-TEK antibody |
||
| STJ29302 | 100 µl | EUR 277 |
|
Description: This gene encodes a receptor that belongs to the protein tyrosine kinase Tie2 family. The encoded protein possesses a unique extracellular region that contains two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin type III repeats. The ligand angiopoietin-1 binds to this receptor and mediates a signaling pathway that functions in embryonic vascular development. Mutations in this gene are associated with inherited venous malformations of the skin and mucous membranes. Alternative splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. |
||
Anti-TEK Antibody |
||
| STJ503257 | 100 µg | EUR 476 |
Anti-TEK Antibody |
||
| STJ503258 | 100 µg | EUR 476 |
TEK Rabbit pAb |
||
| A7222-100ul | 100 ul | EUR 308 |
TEK Rabbit pAb |
||
| A7222-200ul | 200 ul | EUR 459 |
TEK Rabbit pAb |
||
| A7222-20ul | 20 ul | EUR 183 |
TEK Rabbit pAb |
||
| A7222-50ul | 50 ul | EUR 223 |
TEK Conjugated Antibody |
||
| C37274 | 100ul | EUR 397 |
Cancer-Targeting Compound 1 |
||
| HY-U00300 | 1mg | EUR 849 |
Neuromuscular-targeting compound 1 |
||
| HY-U00310 | 20mg | EUR 4803 |
Itch-Targeting Compound 1 |
||
| HY-U00361 | 20mg | EUR 11180 |
Arrhythmic-Targeting Compound 1 |
||
| HY-U00393 | 5mg | EUR 9361 |
Asthma relating compound 1 |
||
| HY-U00412 | 5mg | EUR 2846 |
Arrhythmias-Targeting Compound 1 |
||
| HY-101750 | 20mg | EUR 5683 |
NPS ALX Compound 4a |
||
| HY-103090 | 5mg | EUR 291 |
8-hydroxy Guanosine, compound |
||
| 8OHG15-N-1 | 1 mg | EUR 202 |
8-hydroxy Guanosine, compound |
||
| 8OHG15-N-5 | 5 mg | EUR 590 |
PKM2 inhibitor(compound 3k) |
||
| B8217-25 | 25 mg | EUR 412 |
PKM2 inhibitor(compound 3k) |
||
| B8217-5 | 5 mg | EUR 168 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-.1 | 100 uL/well(10 mM solution) | EUR 23389 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-.25 | 250 uL/well(10 mM solution) | EUR 42042 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-5 | 5 mg/well | EUR 54686 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-.1 | 100 uL/well(10 mM solution) | EUR 4736 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-.25 | 250 uL/well(10 mM solution) | EUR 8518 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-5 | 5 mg/well | EUR 11070 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-.1 | 100 uL/well(10 mM solution) | EUR 5954 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-.25 | 250 uL/well(10 mM solution) | EUR 10722 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-5 | 5 mg/well | EUR 13970 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-.1 | 100 uL/well(10 mM solution) | EUR 11174 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-.25 | 250 uL/well(10 mM solution) | EUR 20118 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-5 | 5 mg/well | EUR 26150 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-.1 | 100 uL/well(10 mM solution) | EUR 3472 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-.25 | 250 uL/well(10 mM solution) | EUR 6198 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-5 | 5 mg/well | EUR 8054 |
CCT251545 analogue, Compound 51 |
||
| A8739-25 | 25 mg | EUR 1442 |
|
Description: CCT251545 analogue, Compound 51 is a potent and selective CDK8/19 inhibitor with IC50 values of 5.1 nM and 5.6 nM, respectively [1]. Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. |
||
CCT251545 analogue, Compound 51 |
||
| A8739-5 | 5 mg | EUR 456 |
|
Description: CCT251545 analogue, Compound 51 is a potent and selective CDK8/19 inhibitor with IC50 values of 5.1 nM and 5.6 nM, respectively [1]. Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. |
||
Anti-TIE2/TEK Antibody |
||
| A01274-1 | 100ug/vial | EUR 334 |
Anti-TIE2/TEK Antibody |
||
| A01274-2 | 100ug/vial | EUR 334 |